We describe the first case of genetically diagnosed congenital dyserythropoietic anemia (CDA) type 1 in a Japanese man. The patient had hemolytic anemia since he was a child, and he developed diabetes, hypogonadism, and liver dysfunction in his thirties, presumably from systemic iron overload. When he was 48 years old a diagnosis was finally made by genetic analysis that revealed a homozygous mutation of CDAN1 gene (Pro1129Leu). His serum hepcidin-25 level was inappropriately low. We conclude that physicians should be aware of the possibility of CDA in a patient with anemia and systemic iron overload at any age.
Introduction
Congenital dyserythropoietic anemia (CDA) is a rare congenital erythropoietic disorder with characteristic morphological abnormalities of the bone marrow cells, ineffective erythropoiesis and systemic iron overload (1) . Three types of CDA are known: types 1, 2 and 3. The genes responsible for types 1 and 2 have recently been identified as CDAN1 and SEC23B, respectively (2, 3) . Both CDA types 1 and 2 are inherited recessively. The incidence of CDA is very rare, and in a recent pan-European survey, only 124 CDA type 1 cases were recorded (4) . To date, several Japanese CDA type 1 cases have also been reported (5-7), but none of them has been genetically proven. Here, we describe in a Japanese adult a case of CDA type 1 with systemic iron overload that was genetically diagnosed in his late forties.
Case Report
A Japanese man was referred to the Kyoto University Hospital for hyperglycemia when he was 38 years old. He had had hemolytic anemia since he was a child, but its etiology had not been determined. He had undergone splenectomy when he was 36 years old, which ameliorated his anemia to some extent. At his first visit to our hospital, his white blood cell count was 6,400/μL; red blood cell count, 1.93×10 6 /μL; hemoglobin (Hb) level, 7.5 g/dL; hematocrit level, 21.0%; mean corpuscular volume, 108.8 fL; platelet count, 365×10 3 /μL; and reticulocyte count, 53×10 3 /μL (Ta- ble 1). He had hepatic dysfunction, with a slightly elevated serum alanine aminotransferase level (68 IU/L), hyperglycemia (blood sugar level of 146 mg/dL and HbA1c level of 6.9%) with very low insulin secretion (serum c-peptide level, <0.1 ng/mL), and hypogonadism with a serum testosterone level lower than 0.2 ng/mL, i.e., very low (reference range, 2.7-10.7 ng/mL). His blood test results also suggested iron overload (transferrin saturation of 95.3% and serum ferritin level of 4,058 ng/mL), and the liver biopsy results revealed marked accumulation of iron in the parenchymal cells. Thus, hemochromatosis, along with liver dysfunction, diabetes and hypogonadism, was diagnosed. Insulin therapy was then started. Occasional phlebotomy was also started to remove excess iron and to gradually decrease his serum ferritin and alanine aminotransferase levels to within the reference ranges (Table 1) . When he was 46 years old, a series of intensive diagnostic examinations were started. The findings of the biochemical analyses for erythrocyte membrane disorders or unstable hemoglobinopathies were all negative. The bone marrow examination revealed marked erythroid hyperplasia (the myeloid to erythroid ratio of 0.34) and remarkable dysplastic features in the erythroid cells, with megaloblastoid changes and multinuclear cells (Fig. 1A-E) . However, no significant dysplasia was observed in the granulocytic or megakaryocytic series (Fig. 1A, B) , and no ring sideroblasts were observed in the iron staining. When he was 48 years old, we obtained his written informed consent and approval by the ethics committee of Kyoto University to perform a genetic analysis for indicators of hereditary iron disorders in his peripheral blood cells. The results of the genetic analyses for pyruvate kinase deficiency and thalassemia syndromes were all negative. There were no mutations in the exons and the exon-intron borders of hereditary hemochromatosis genes including HFE, TFR2, HJV, HAMP, and SLC40A1. However, a homozygous mutation in CDAN1 ex26 c.3503 C>T (Pro1129Leu) was detected, consistent with CDA type 1 (Fig. 2) . When we reviewed his bone marrow specimen, internuclear bridges that connected two separate erythroblasts were occasionally observed (7 bridges in 500 erythroblasts, Fig. 1F-J) . His serum hepcidin-25 level was 0.8 ng/mL [reference range, 2.3-37 ng/mL; analyzed with a quantitative liquid chromatography coupled with tandem mass spectrometry method (8) ]. The growth differentiation factor-15 (GDF15) level was 8,469 pg/mL (reference range, 215-835 pg/mL; analyzed with a commercial ELISA kit from R&D, Minneapolis, MN). The patient had two siblings, a brother and a sister; both were in good health. There was no significant family history except that his mother had anemia of undetermined etiology, and his paternal grandfather had diabetes. He declined genetic analysis of his family for the CDAN1 gene.
Discussion
We encountered an adult patient with hemolytic anemia with various symptoms caused by systemic iron overload, who turned out to have a genetic mutation consistent with CDA type 1. To our knowledge, this is the first documented case of CDA type 1 in a Japanese with CDAN1 gene mutation. Dgany et al. identified the same CDAN1 gene mutation as the current case in a French Polynesian family (2) . CDAN1 is located on chromosome 15q15.1-15q15.3, and it codes for a nuclear protein, codanin-1, the human homolog of discs lost (dlt) which is required for cell survival and cell cycle progression in Drosophila (9) . The diagnosis of CDA type 1 has usually been made from clinical features together with characteristic morphological features of the bone marrow cells such as binucleated erythroblasts, and internuclear bridges between the erythroid cells. As codanin-1 is essential for proper cellular trafficking of the heterochromatin protein HP1-α (10), defects of this protein may result in such morphological abnormalities. In the current case, the bone marrow examination results showed numerous binucleated erythroblasts, but the internuclear bridges, which are much more specific features of this disorder, were observed in less than 3% of the erythroblasts and were overlooked in the first inspection (Fig. 1) . Therefore, making a definitive diagnosis of CDA from bone marrow cell morphology alone can sometimes be difficult.
CDA types 1 and 2 are known to be accompanied by iron overload. Similar to hereditary hemochromatosis, inappropriately low production of hepcidin, the central regulator of systemic iron homeostasis, has been proposed as the etiology of iron overload in CDA (11) . As the main function of hepcidin is to downregulate the expression of ferroportin, the only known cellular iron exporter of mammals, downregulation of hepcidin results in an increase in ferroportin expression, thereby increasing iron absorption from the intestine and causing systemic iron overload. A previous report demonstrated marked increases of GDF15 in the serum of CDA type 1 patients (12). GDF15, a humoral factor belonging to the transforming growth factor-β superfamily, has been shown to suppress hepatic production of hepcidin (13) . Consistent with the previous reports, systemic iron overload was induced in the current case without repeated red cell transfusions, the serum GDF15 level was remarkably elevated, and the serum hepcidin-25 level was inappropriately low. Thus, we postulate that serum hepcidin-25 and GDF15 are useful markers for CDA.
CDA is generally regarded as a pediatric disease because the initial symptoms, such as anemia, jaundice, and splenomegaly, usually appear in the first decade. However, the current case was diagnosed when the patient was in his late forties, and in the pan-European survey, CDA was diag-nosed in a substantial proportion of patients who were middle-aged or older (4) . Early diagnosis of CDA is important because iron chelation therapy (or phlebotomy if anemia is mild) should be started as early as possible to avoid iron overload, which can cause irreversible tissue damage. In addition, interferon-α is known to be effective for ameliorating anemia and iron accumulation in patients with CDA type 1, although the precise mechanism is still unknown (14) . The survey data and our findings of the current case suggest that we should be aware of the possibility of CDA in patients with anemia and systemic iron overload at any age.
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